INS and diabetes mellitus: Application of glibenclamide (1–10 μM), a well-known diabetes drug that promotes insulin secretion by inhibiting KATP22, to RINm5F cells depolarized the membrane as expected; however, in the presence of glyH-101 (10 μM), the glibenclamide-induced membrane depolarization was significantly reduced (Fig. 2e).